U.S. Department of Health and Human Services  —  National Institutes of Health

Rapastinel

Autogenerated by for
Created on Tue, 2016-09-13 11:59, last updated on Tue, 2016-09-13 11:59

I Printed This

Remix It

Vertical Tabs

QR Code for https://3dprint.nih.gov/discover/3dpx-003708

Rating

1
Average: 1 (1 vote)

Licensing

Comments

1

View Comments

Comments

Tue, 2016-09-13 12:09

Rapastinel (INN) (former developmental code names GLYX-13, BV-102) is a novel antidepressant that is under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder.